Peroxiredoxin 3 (PRDX3), a member of the peroxiredoxin family, is a mitochondrial antioxidant enzyme critical for regulating cellular redox homeostasis. It primarily neutralizes reactive oxygen species (ROS) generated during oxidative phosphorylation, protecting mitochondrial components from oxidative damage. PRDX3 also modulates redox-dependent signaling pathways involved in apoptosis, proliferation, and inflammation. Its dysregulation is linked to various diseases, including cancer, neurodegenerative disorders, and cardiovascular conditions.
Antibodies targeting PRDX3 are essential tools for studying its expression, localization, and function. These antibodies enable the detection of PRDX3 in techniques like Western blotting (WB), immunohistochemistry (IHC), and immunofluorescence (IF). They are widely used to explore PRDX3's role in mitochondrial stress responses, its interaction with other redox-regulating proteins, and its potential as a biomarker in pathological conditions. For instance, reduced PRDX3 levels in certain cancers correlate with poor prognosis, while its overexpression may mitigate oxidative injury in neurodegenerative models.
Commercial PRDX3 antibodies are typically raised against specific epitopes of human or murine PRDX3. with cross-reactivity validated across species. Researchers prioritize antibodies with high specificity, often verified via knockout controls or recombinant protein validation. Applications extend to both basic research and clinical studies, particularly in understanding mitochondrial dysfunction and oxidative stress mechanisms. Proper validation ensures reliable results, minimizing off-target effects in complex biological samples.